Sarepta Therapeutics (SRPT) Sees Increased Cash Burn

In discussions with certain third parties on April 22, 2014, Sarepta Therapeutics (Nasdaq: SRPT) disclosed that it estimates that cash, cash equivalents and invested cash as of March 31, 2014 was approximately $233.1 million, consisting of approximately $49.1 million of cash and cash equivalents, approximately $176.1 million of short term investments and approximately $7.9 million of restricted investments. Given the acceleration of our anticipated New Drug Application filing and our proposed commencement of numerous additional clinical trials, we expect our cash used in operating activities to increase significantly from our previous estimates. The Company has not closed its books for the first quarter of 2014 and its independent registered public accountants have not completed their review of financials for the first quarter of 2014, therefore, actual results may differ materially from these estimates due to the completion of the Company’s financial closing procedures, final adjustments and other developments that may arise between now and the time the financial results for the Company’s first quarter are finalized.

You May Also Be Interested In

• Lockheed Martin (LMT) Tops Q1 EPS by 53c, Beats on Revenue; Offers FY24 Guidance
• Philip Morris International (PM) Tops Q1 EPS by 9c; raises guidance
• Spotify (SPOT) jumps 10% as Q1 revenue, gross margins beat Street's estimates